Exploration of predictive biomarkers in checkpoint inhibitor, nivolumab, for recurrent esophageal squamous cell carcinoma after standard therapy

Exploration of predictive biomarkers in checkpoint inhibitor, nivolumab, for recurrent esophageal squamous cell carcinoma after standard therapy - E-CIRCUIT

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000042908

Enrollment

Registered

2021-01-05

Start date

2021-01-05

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Esophageal squamous cell carcinoma

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with esophageal squamous cell carcinoma who were treated with nivolumab in Department of Gastrointestinal Tract Surgery, Fukushima Medical University Hospital.

Exclusion criteria

Exclusion criteria: None.

Design outcomes

Primary

Measure	Time frame
Immunologic parameters	—

Countries

Japan

Contacts

Public ContactKosaku Mimura

Fukushima Medical University Department of Gastrointestinal Tract Surgery

kmimura@fmu.ac.jp024-547-1259

Outcome results